Novo Nordisk suffers Wegovy defeat to Viatris in patent court
It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
Pharmaceutical industry to grow 4% annually towards 2030
For subscribers
Zealand Pharma CEO: "We've never been stronger"
For subscribers
Eli Lilly's head of diabetes and obesity retires
For subscribers
DNB expects ALK's tablet sales to recover in 2024
For subscribers
Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom
The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.For subscribers
Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.For subscribers
Low share price may knock Galecto off the stock exchange
Nasdaq has requested that the biotech company raise its share price to above USD 1.For subscribers
Fujifilm expands management with former Leo executive
The contract manufacturer has hired a chief people officer with immediate effect.For subscribers
Snack maker keeps an eye on Novo Nordisk's obesity drug
”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.FDA approves Novo Nordisk drug to treat rare condition
The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.For subscribers
Genmab has officially opened its new headquarters
The CEO describes the new premises as a symbol of the company’s commitment to advancing science and innovation.For subscribers
Galecto to lay off 70% of its workforce - announces plans to explore "strategic alternatives"
”Biotech is great when things are going well and hard when things are going badly,” says the company’s CEO, Hans Schambye.For subscribers
Minister: Several countries are against key proposal in controversial EU reform
Several countries will oppose a change in data protection in the EU, Denmark’s Minister for Industry, Business and Financial Affairs tells MedWatch.For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.For subscribers
FDA to support new orphan drugs through pilot program
Companies developing drugs for rare diseases can apply to be part of a new FDA pilot program, starting at the beginning of the year.For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.For subscribers
Country Manager: Indians will have to wait for Wegovy until 2026
Up to 40% of the female population aged 30-49 in India is overweight.For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.For subscribers
Johnson & Johnson shows positive results in lung cancer study
The Genmab partner’s study has tested antibody treatment Rybrevant and drug candidate Lazertinib in comparison to AstraZenaca’s cancer drug, Tagrisso.For subscribers
Novo Holdings makes another investment in US biotech company
The money will be used to bring the company’s two drug candidates into phase II as treatments for various lung diseases.For subscribers
Kallyope enters Phase II with obesity and diabetes tablet
US biotech company Kallyope’s anti-obesity and diabetes tablet could be a serious competitor to the current glp-1 analogs, according to the company’s executives.For subscribers
Investor alliance urges pharmaceutical companies to improve environmental impact
A number of pharmaceutical companies have been identified as companies that can help reverse the loss of nature and biodiversity.For subscribers
Ascendis CFO sells shares worth DKK millions
The deal happens just over a week after Ascendis began the rollout of its weekly growth hormone, Skytrofa, in Europe.For subscribers
